Bexion Pharmaceuticals Continues to Gain Support from National Cancer Institute

The grant entitled 'SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme' was awarded September 28, 2010 and covers a two year period.

Related Posts

Comments are closed.